Search

A new study on P2Y12 platelet inhibitors has been published, focusing on the use of Cangrelor therapy in patients with temporary mechanical circulatory support or as a bridge to a procedure. The study retrospectively reviewed adult patients who received platelet function testing (PFT) with the VerifyNow P2Y12 assay while on Cangrelor. The results showed that PFT-guided Cangrelor dose adjustment may allow for lower, individualized dosing while preventing stent thrombosis. Additionally, this approach was associated with a median drug cost savings of $1605.60 compared to empiric dosing. [Extracted from the article]